Boehringer Ingelheim is a group of companies dedicated to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. It is one of the world’s 20 leading pharmaceutical companies.

Figures (2008)

• 138 affiliated companies in 47 countries
• 41,300 employees
• EUR 11,595 million net sale

The objectives and beliefs of Boehringer Ingelheim can be summed up in a single phrase: Value through Innovation. This vision has helped us to build on our strengths and make the most of our distinctive character. In a competitive and fast-changing world, the value of products, services and companies is constantly changing. Real customer value today can only be created by constantly developing new solutions and doing what we already do better.

Boehringer Ingelheim was founded in Ingelheim am Rhein (Germany) in 1885, where the corporate headquarters is still located.

• Prescription Medicines
• Consumer Health Care
• Industrial Customer
• Biopharmaceuticals
• Pharmaceuticals Production
• Pharma Chemicals
• Animal Health

We are spending 22% of net sales in our largest business segment Prescription Medicines (2008) on R&D. We have four main R&D sites and three smaller specialised sites worldwide, which focus on seven major therapeutic areas:

• Respiratory diseases
• Cardiovascular diseases
• Central nervous system (CNS) diseases
• Oncology
• Virology
• Metabolic diseases
• Immunology and Inflammation